58
Participants
Start Date
December 31, 2009
Primary Completion Date
September 30, 2014
Study Completion Date
February 28, 2015
AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
IV AR-67 administered once daily for 5 days on an every 21-day cycle
North Shore - Long Island Jewish Hospital/Monter Cancer Center, Lake Success
Derrick L Davis Forsyth Regional Cancer Center, Winston-Salem
Duke University Medical Center - The Preston Robert Tisch Brain Tumor Center, Durham
University of Kentucky - Markey Cancer Center, Lexington
The Ohio State University - James Comprehensive Cancer Center, Columbus
Northwestern University - Robert H Lurie Comprehensive Cancer Center, Chicago
University of Utah - Huntsman Cancer Center, Salt Lake City
University of Calgary - Tom Baker Cancer Center, Calgary
University of Alberta - Cross Cancer Institute, Edmonton
Lead Sponsor
Arno Therapeutics
INDUSTRY